Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $3.86 Consensus Target Price from Brokerages

by · The Cerbat Gem

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $3.8571.

Several brokerages have weighed in on RVPH. Benchmark lowered their target price on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research note on Monday, September 15th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Reviva Pharmaceuticals in a report on Wednesday, November 19th. Citigroup restated a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. Maxim Group lowered their price target on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, August 15th. Finally, Roth Capital reissued a “buy” rating and issued a $3.00 target price (down previously from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th.

Read Our Latest Report on RVPH

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Armistice Capital LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter worth $1,026,000. 683 Capital Management LLC purchased a new position in shares of Reviva Pharmaceuticals in the 2nd quarter worth about $381,000. Persistent Asset Partners Ltd lifted its stake in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares in the last quarter. Millennium Management LLC lifted its position in Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after buying an additional 223,178 shares in the last quarter. Finally, Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the third quarter worth about $37,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ:RVPH opened at $0.59 on Tuesday. Reviva Pharmaceuticals has a one year low of $0.25 and a one year high of $4.28. The stock has a market capitalization of $68.02 million, a price-to-earnings ratio of -1.29 and a beta of -0.02. The company has a 50-day simple moving average of $0.55 and a 200-day simple moving average of $0.55.

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.05. As a group, research analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

Recommended Stories